MXCT
MXCT
NASDAQ · Life Sciences Tools & Services

Maxcyte Inc

$0.71
+0.01 (+1.18%)
As of Apr 1, 3:15 PM ET ·
Financial Highlights (FY 2026)
Revenue
41.47M
Net Income
-44,086,093
Gross Margin
81.6%
Profit Margin
-106.3%
Rev Growth
+4.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 81.6% 81.6% 41.4% 41.4%
Operating Margin -132.5% -119.3% 7.9% 8.9%
Profit Margin -106.3% -101.0% 7.9% 6.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 41.47M 39.70M 11.59M 9.98M
Gross Profit 33.85M 32.41M 4.80M 4.13M
Operating Income -54,969,972 -47,360,688 910.9K 885.5K
Net Income -44,086,093 -37,983,423 913.3K 656.0K
Gross Margin 81.6% 81.6% 41.4% 41.4%
Operating Margin -132.5% -119.3% 7.9% 8.9%
Profit Margin -106.3% -101.0% 7.9% 6.6%
Rev Growth +4.5% +4.5% +8.1% +21.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 17.20M 19.69M
Total Equity 38.88M 41.65M
D/E Ratio 0.44 0.47
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -50,525,635 -45,949,983 1.25M 1.22M
Free Cash Flow 402.0K 324.3K